Creative Planning Acquires 1,909 Shares of argenx SE (NASDAQ:ARGX)

Creative Planning lifted its holdings in argenx SE (NASDAQ:ARGX) by 54.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,437 shares of the company’s stock after acquiring an additional 1,909 shares during the period. Creative Planning’s holdings in argenx were worth $2,947,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. Profund Advisors LLC raised its position in shares of argenx by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after acquiring an additional 28 shares in the last quarter. Wealth Alliance increased its position in argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after buying an additional 29 shares in the last quarter. GAMMA Investing LLC increased its position in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares in the last quarter. Toronto Dominion Bank increased its position in argenx by 16.5% in the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after buying an additional 43 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in argenx by 3.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock valued at $737,000 after buying an additional 52 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Truist Financial boosted their target price on argenx from $480.00 to $540.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. Robert W. Baird boosted their target price on argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Oppenheimer raised argenx from a “market perform” rating to an “outperform” rating and set a $546.00 target price for the company in a research report on Tuesday, July 23rd. Citigroup boosted their target price on argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Finally, Raymond James reiterated a “strong-buy” rating and set a $605.00 price target on shares of argenx in a research note on Thursday, October 10th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $550.44.

argenx Stock Up 1.0 %

Shares of NASDAQ ARGX opened at $556.83 on Friday. argenx SE has a twelve month low of $327.73 and a twelve month high of $571.97. The stock’s 50 day moving average price is $534.84 and its 200-day moving average price is $459.81. The company has a market capitalization of $33.09 billion, a PE ratio of -98.38 and a beta of 0.63.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The firm had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. During the same quarter in the previous year, the business earned ($1.69) EPS. As a group, research analysts expect that argenx SE will post -0.37 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.